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Sera from cats experimentally infected with five isolates of feline immunodeficiency virus (FlY) from various
geographical regions and from FIV enzyme-linked immunosorbent assay-seropositive field cats from four
European countries neutralized the Petaluma strain of FIV (FlV-P), originally isolated in California, at high
titers. In addition, FIV-P and a European isolate proved equally susceptible to neutralization by all sera tested.
Coupled with observations by Fevereiro et al. (M. Fevereiro, C. Roneker, A. Laufs, L. Tavares, and F. de
Noronha, J. Gen. Virol. 72:617-622, 1991), these findings indicate that most if not all FIV strains circulating
in Europe and the United States share important neutralization-inducing epitopes.
Feline immunodeficiency virus (FIV), a widespread cause
of disease in domestic cats (2, 9, 24), shares many properties
with human immunodeficiency virus (HIV) and is therefore
considered a suitable model for studying aspects of AIDS
pathogenesis and treatment which cannot be easily ad-
dressed with humans (15, 19). Nonetheless, little is known
about the ability of FIV to induce neutralizing antibodies
(NA). Using a procedure based on infectivity inhibition,
Fevereiro et al. (5) found an antibody that neutralizes the
prototype Petaluma strain of FIV (FIV-P), originally isolated
in California (16), in a limited number of domestic cats from
the United States as well as in cats experimentally infected
with FIV-P. In the present study, using a recently developed
syncytium formation inhibition assay, we showed that FIV
strains which circulate in the United States and in Europe
are extensively cross-neutralized.
The neutralization assay used has been described else-
where (22). Briefly, 0.1-ml volumes of twofold dilutions
(from 1:8 to 1:16,096) of sera heated at 56°C for 30 min were
mixed with 0.1 ml of FIV diluted to contain 1,000 syncytium-
forming units/ml, incubated at room temperature for 1 h, and
then inoculated into 0.5 ml of medium in duplicate wells of
24-well plates which were seeded with 104 Crandell feline
kidney (CrFK-MESNA) cells adapted to grow in a medium
containing a low concentration of fetal bovine serum. Each
plate included control immune and negative sera. Six days
later, the plates were stained with 0.2% crystal violet in 30%
methanol and examined microscopically. Only syncytia con-
taining seven or more nuclei were counted. The neutralizing
titer was expressed as the reciprocal of the highest dilution
of serum which prevented the formation of syncytia. Unless
otherwise stated, FIV-P was used in the neutralization
assay. In some experiments, the Dutch isolate Amsterdam-6
(FIV-A6), which was obtained from a free-roaming cat in the
Netherlands and adapted to replication in CrFK-MESNA
cells, was also used. Both FIV-P and FIV-A6 consistently
produce syncytia on freshly infected CrFK-MESNA cells.
The viral stocks used ranged in titer between 4 x 103 and 5
x 104 syncytium-forming units/0.1 ml.
* Corresponding author.
We first examined the sera of specific-pathogen-free (SPF)
cats infected with various FIV isolates. Viruses used for
infection included FIV-P, two Italian isolates (Pisa-Ml and
Pisa-M2 [FIV-M2]), one British isolate (Glasgow-8), one
Dutch isolate (Amsterdam-19), and the viral progeny of an
infectious molecular clone (19kl) of the last virus (20). The
genetic relatedness of these isolates was the subject of a
recent report (18). All of the sera of infected cats neutralized
FIV with titers ranging from 512 to 8,192, whereas preinfec-
tion sera diluted 1:8 did not. The presence of NA correlated
with reactivity in an enzyme-linked immunosorbent assay
(ELISA) for FIV antibody (CITE Combo FIV-FeLV; Ag-
ritech Systems, Portland, Maine) (data not shown). Figure 1
shows the kinetics of NA production in SPF cats inoculated
with FIV-M2. Low levels of NA were already detectable in
some cats at day 5 postinfection (Fig. 1, insert), but these
antibodies were most likely acquired passively with the
plasma used to infect the animals, as the titers declined
steadily in the following days. Actively produced NA be-
came clearly evident at 5 to 6 weeks of infection (approxi-
mately at the time of seroconversion, as detected by other
methods [reference 13 and data not shown]), reached a
plateau 3 to 4 months later, and then remained stable for the
subsequent period of observation. As shown by periodic
isolation of virus from the peripheral blood mononuclear
cells by a standard procedure (2), all cats in this group
developed a persistent FIV infection.
We then examined sera obtained from naturally infected
domestic cats from different European countries. The do-
nors were of many breeds and ages and of both sexes and
had different living conditions. Infection was determined
serologically by ELISA and in most Italian cats was con-
firmed by virus isolation. The sera of 43 out of 45 infected
cats neutralized FIV at titers ranging from 32 to 4,096 (the
other two serum samples, diluted 1:8, reduced syncytium
formation by over 70%). In contrast, the sera of 17 out of 19
noninfected cats were not reactive at a 1:8 dilution. Only two
serum samples from culture-negative, ELISA-seronegative
cats showed titers of 8 and 16, respectively. In the infected
animals, NA titers appeared unrelated to the country of
origin (Table 1) or to the clinical status of the cats (data not
shown).
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FIG. 1. NA production in six SPF cats inoculated intravenously with FIV-M2 at an age of 4 to 5 months. This virus is propagated in vivo
by monthly passages in SPF cats and at the dose used (2 ml of freshly collected blood) leads to a positive FIV ELISA in 4 to 6 weeks and
to a reduction in the number of circulating CD4+ lymphocytes by almost two-thirds in 1 year (10). During the period of observation, one cat
showed progressive emaciation and was killed. The insert shows in more detail the NA titers detected during the first 40 days of infection (+
and - indicate reactivity and nonreactivity, respectively, in the ELISA).
TABLE 1. FIV NA in sera of FIV ELISA-negative and -positive
field cats from different European countries
NA titer
ELISA result and No. of serum No. of serum
country of origin' samples samples with 95%examined NA Meanb confidence
limits
Seronegative, Italy 19 2 10
Seropositive
Italy 21 21 495 213-1,150
The Netherlands 6 6 287 70-1,179
United Kingdomc 14 12d 1,124 53-2,488
Switzerland' 4 4 512
a All but two FIV-seronegative cats examined were clinically healthy. In
contrast, many infected animals presented clinical manifestations (gingivitis,
diarrhea, dermatitis, upper respiratory tract infections, anorexia, emaciation,
pyrexia, anemia, lymphopenia, lymphadenopathy, or neurological signs)
compatible with FIV infection.
b Geometric mean of titers Z8. The means of the infected groups are not
significantly different.
c Sera provided by Oswald Jarrett, University of Glasgow.
d At the lowest dilution tested (1:8), the two serum samples that were
scored as NA negative reduced FIV-induced syncytium formation by over
70%.
' Sera provided by Hans Lutz, University of Zurich.
The previous data demonstrated the existence of a high
degree of serological cross-reactivity among FIV strains
which circulate in Europe and the United States. To further
investigate this aspect of FIV, we simultaneously titrated
against FIV-P and FIV-A6 a panel of 15 serum samples
known to contain NA. The sera neutralized the two isolates
with similar efficiencies, irrespective of the virus used to
immunize the animals or the geographical origin of the
donors (data not shown).
The results presented above are at variance with those
reported for HIV, whose sensitivity to antibody-mediated
neutralization is generally markedly influenced by the source
of sera (12). As prior studies with HIV had indicated that, in
vitro, certain antibodies may cause a dissociation between
syncytium formation and virus replication and/or produce
neutralization even if added to cultures after virus is bound
to cells (14, 23), we investigated how seropositive cat sera
bring about the inhibition of syncytium formation by FIV.
To address this point, we studied the effect of thoroughly
washing off the input virus-serum mixtures after absorption.
The representative data presented in Table 2 show that
inhibition of syncytium formation is not dependent on the
continuous presence of serum in the test cultures and
correlates well with inhibition of viral antigen accumulation
in the supernatants. In further studies, the addition of
high-titer neutralizing sera to cell cultures that had been
infected 4 h earlier did not prevent the formation of the
expected numbers of syncytia, although the syncytia pro-
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TABLE 2. Effect of removing virus-serum inocula on neutralization, as determined by syncytium formation and viral antigen production
Results with serum:
M2-IV M2-VIIb
Serum
dilution With removal" With removal
No. of syncytiaa No. of syncytia
without removal No. of Optical without removal No. of Optical
syncytia densityc syncytia density
1:256 0 0 0.211 0 0 NDd
1:512 0 0 0.203 0 0 ND
1:1,024 0 0 0.219 0 0 0.216
1:2,048 0 0 0.263 0 0 0.213
1:4,096 0 0 0.271 0 0 0.210
1:8,192 4 ± 2 0 0.242 0 16 ± 5 0.473
1:16,384 18 ± 4 14 ± 4 0.846 8 22 ± 6 0.477
FIV alone 61 ± 8 59 ± 10 2.708
No FIV 0 0 0.227
a Mean ± standard deviation.
b Four hours after inoculation, that is, at a time when most FIV has become absorbed to CrFK-MESNA cells but no syncytia have formed (22), the FIV-serum
inocula were washed off and replaced with fresh medium.
c At the end of the 6-day incubation period, the cultures were examined by ELISA for FIV p24 antigen content as well as for syncytia. The p24 assay was
performed on pooled supematants of the cultures as described elsewhere (21), with minor modifications.
d ND, not determined.
duced were smaller (data not shown). These results show
that inhibition of syncytium formation is due to a true
neutralization of FIV infectivity prior to its entry into cells
and not to down-regulation of syncytium formation or other
mechanisms.
This study confirms recent findings (5) showing that cats
develop high-titer NA early after FIV infection. NA may
contribute to the long incubation period between infection
and illness observed in FIV-infected cats as well as to the
fact that FIV transmission in utero is a rare event which
possibly occurs only during primary infection (4, 15, 24, 25).
However, FIV was readily isolated from the peripheral
blood mononuclear cells of animals with high levels of NA in
their sera, indicating that NA are unable to terminate an
established FIV infection. This is in keeping with previous
results (5) and with our present understanding of the role of
NA in HIV type infection (11, 12). It has been suggested that
NA mediate the reduction of high-titer viremia which occurs
in human plasma soon after infection (1). Nevertheless, FIV
could be isolated from plasma regardless of the NA titers
(10).
The neutralizing activity found at low titers in few appar-
ently noninfected cats deserves further investigation. Since
it was observed in cats who were also negative by Western
blot (immunoblot) assay (data not shown), the result does
not seem to stem from the low sensitivity of the ELISA
used. Since it was detected in field cats but not in SPF cats,
explanations to be considered include cross-reactivity of
FIV with other cat pathogens (cats singly infected with feline
leukemia virus or feline syncytium-forming virus, however,
tested negative), the possibility that the neutralization test
detects FIV infections not detected by other currently used
serological methods (6, 8), the possibility that NA persist
longer than other antibodies and represent footprints of an
eradicated FIV infection, and the possible existence of
nonspecific inhibitors.
However, the most important finding of the present study
is the large degree of cross-neutralization exhibited by FIV
isolates from different geographical areas, indicating that
FIV contains one or more highly conserved neutralization
epitopes. This information may be useful in the preparation
of effective vaccines. HIV, which can be considered the
human counterpart of FIV, also contains regions which elicit
broadly reactive neutralizing responses (3, 7, 11, 12), though
its env gene variability appears to be higher than that of FIV
(17). We are currently trying to identify the FIV epitope(s)
involved in neutralization.
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